News & Media

Read the latest news from Cell to Cure.

The Cell2Cure core technology has been granted patent rights in Canada

Cell2Cure featured by Tech Journal »Ingeniøren«

Enrolment finalized in the lung transplantation phase I-II clinical trial

Cell2Cure has treated the first patient with diabetic foot ulcer in the STEMFOOT (Phase I study)

The Danish Medicines Agency has approved the phase I clinical trial with allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASC) treatment of children with autism and leaky gut syndrome

Ethical approval for the allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASC) phase I clinical trial in children with autism and leaky gut syndrome

The Danish Medicines Agency has approved a Phase I trial treating diabetic foot ulcer with allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs)

The Cell2Cure core technology has been granted patent rights in Australia

Patient enrollment finalized in the Phase II trial testing allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs) in Sjögren’s syndrome

Publication of phase I results of allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASC) treatment of patients with radiation-induced Xerostomia

Cell2Cure enters a collaboration agreement with Endeavour Cells ApS

Cell2Cure enters a sublicense agreement with Endeavour Cells ApS

Collaboration agreement between Cell2Cure and Cbio A/S

Allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASCs) in Phase II testing in Salivary gland re-generation

Completion of allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASCs) in a Heart failure trial

Allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASCs) in a lung transplantation trial

Cell2Cure is part of testing allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASCs) to reestablish nerve conduction in the heart

Allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASCs) in Phase II testing in Sjögren’s syndrome

Cell2Cure partner in a new Stem Cell Center

Publication of phase I trial results – allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASCs) treatment in Sjögren’s syndrome